Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
16/07/2026 11:47
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal July 16 (Reuters) - Eli Lilly LLY.N said on Thursday it would acquire psychedelic drug developer AtaiBeckley ATAI.O for up to $3.8 billion, entering the race to develop psychedelic treatments for depression and other mental health disorders.
(Reporting by Kunal Das and Puyaan Singh in Bengaluru; Editing by Sriraj Kalluvila)
Recent news on AbbVie
See all newsBrief: Abbvie Reaches Agreement With The Pan-Canadian Pharmaceutical Alliance (Pcpa) For Elahere® In Platinum-Resistant Ovarian Cancer
Eli Lilly hits record high as healthcare stocks rally
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96